According to the US “The Wall Street Journal” Web site March 29 reported stroke treatment maleate cinepazide (cinepazide) quit Spain, Italy and France in the late 1980s and 1990s, because it was reported that taking this medicine It can cause blood diseases. However, according to Credit Suisse Securities research institutions show that in 2010, it has become China’s best-selling drugs.
In fact, maleic acid cinepazide been made Sihuan Pharmaceutical Holdings Group Ltd. (00460.HK, hereinafter referred to as “Sihuan”) dominate the market with new drugs last year protection period expires, only competing drugs have been listed. “Our company has never interviewed, there is no relevant departments in charge of this thing, you write whenever you want it, do not tell us.” When the “China Business” reporter interviewed on this issue, Sihuan Pharmaceutical official said so.
According to the “Wall Street Journal” reported, industry experts say, pharmaceutical companies would have to start selling the test and not to market the drug in other countries in China. In response, Beijing Ding Chen Management Consulting Co., Ltd. founder Shili Chen told reporters that the delisting of drugs abroad in domestic sales is not the case. “The vast majority of foreign drugs into the country are very formal and the process is very strict, but also some foreign pharmaceutical companies are good at loopholes, not only in the country, is in the rest of the world if we find no strict restrictions, also by modifying the data of drugs toxicity hiding for sale. “